According to an exclusive report from Reuters, drugmakers Valeant Pharmaceuticals International Inc, Actavis Plc and Mylan Inc have all expressed interest in buying Pfizer Inc's branded generics business, but no active discussions are going on at this time, according to three people close to the matter.
As of January 1, Pfizer officially divided into three separate business units. The current unit of interest is Pfizer's "value" products business, which consists of off-patent products and products soon-to-be off patent.
The deal has the potential to catapult a buyer into the ranks of the biggest pharmaceutical companies in the world.
Read the Reuters press release